As far as we know, this is the first study to attempt to use TGFβ signaling responsive SMAD4 regulated genes to classify ovarian cancer patients into different sub-types of patient groups, as well as predict poor survival from good survival populations with statistical significance (Figure 5). The gene discussed is SMAD4; the disease is ovarian carcinoma.